Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Capital Leases (2019 - 2023)

Historic Capital Leases for Alaunos Therapeutics (TCRT) over the last 5 years, with Q3 2023 value amounting to $864000.0.

  • Alaunos Therapeutics' Capital Leases fell 6298.2% to $864000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $864000.0, marking a year-over-year decrease of 6298.2%. This contributed to the annual value of $2.2 million for FY2022, which is 5157.15% down from last year.
  • Per Alaunos Therapeutics' latest filing, its Capital Leases stood at $864000.0 for Q3 2023, which was down 6298.2% from $1.2 million recorded in Q2 2023.
  • Over the past 5 years, Alaunos Therapeutics' Capital Leases peaked at $4.5 million during Q4 2021, and registered a low of $647000.0 during Q3 2019.
  • For the 5-year period, Alaunos Therapeutics' Capital Leases averaged around $2.0 million, with its median value being $1.7 million (2020).
  • Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 15579.6% in 2020, then plummeted by 6298.2% in 2023.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' Capital Leases stood at $647000.0 in 2019, then surged by 517.47% to $4.0 million in 2020, then grew by 13.09% to $4.5 million in 2021, then crashed by 51.57% to $2.2 million in 2022, then tumbled by 60.51% to $864000.0 in 2023.
  • Its last three reported values are $864000.0 in Q3 2023, $1.2 million for Q2 2023, and $2.0 million during Q1 2023.